The pharmacokinetics of pergolide in Parkinson's disease

被引:20
|
作者
Blin, O [1 ]
机构
[1] CHU Timone, CPCET, CNRS, FRE 2109,Inst Physiol & Clin Neurosci, F-13385 Marseille 5, France
关键词
dopamine agonist; pergolide; pharmacokinetics; Parkinson's disease;
D O I
10.1097/00019052-200312001-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Three decades of research have led to a fuller understanding of the pharmacokinetics of pergolide. Pergolide is rapidly absorbed following oral dosing, reaching peak plasma concentrations within 2-3 h. It is about 90% protein bound yet has negligible drug interactions. Pergolide undergoes extensive first-pass metabolism and is completely eliminated within 4-5 days. The metabolism/elimination profile varies between patients but is consistent within the individual, highlighting the importance of careful titration to an effective dose. Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia.
引用
收藏
页码:S9 / S12
页数:4
相关论文
共 50 条
  • [21] The effectiveness of pergolide and cabergoline as an adjunct to levodopa in Parkinson's disease
    Subutay-Oztekin, N
    Oztekin, F
    [J]. JOURNAL OF NEUROLOGY, 2004, 251 : 130 - 130
  • [22] Comparative study of effects of bromocriptine and pergolide in Parkinson's disease
    deYebenes, JG
    Ruiz, PJG
    Pernaute, RS
    [J]. REVISTA DE NEUROLOGIA, 1997, 25 (145) : 1343 - 1345
  • [23] Trial of subtherapeutic pergolide in de novo Parkinson's disease
    Grosset, K
    Grosset, D
    Lees, A
    [J]. MOVEMENT DISORDERS, 2005, 20 (03) : 363 - 366
  • [24] Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline
    Kenangil, Gulay
    Ozekmekci, Sibel
    Koldas, Lale
    Sahin, Taylan
    Erginoz, Ethem
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2007, 109 (04) : 350 - 353
  • [25] PERGOLIDE MESYLATE AND IDIOPATHIC PARKINSON DISEASE
    TANNER, CM
    GOETZ, CG
    GLANTZ, RH
    GLATT, SL
    KLAWANS, HL
    [J]. NEUROLOGY, 1982, 32 (10) : 1175 - 1179
  • [26] Heart valvular disease in patients with Parkinson's disease treated with Pergolide and/or Levodopa
    Ozer, F.
    Tiras, R.
    Cetin, S.
    Ozturk, O.
    Aydemir, T.
    Ozben, S.
    Meral, H.
    Kizkin, S.
    Bader, H.
    [J]. MOVEMENT DISORDERS, 2006, 21 : S518 - S518
  • [27] TREATMENT OF ADVANCED PARKINSON DISEASE WITH PERGOLIDE
    LIEBERMAN, A
    GOLDSTEIN, M
    LEIBOWITZ, M
    NEOPHYTIDES, A
    KUPERSMITH, M
    PACT, V
    KLEINBERG, D
    [J]. NEUROLOGY, 1981, 31 (06) : 675 - 682
  • [28] Early combination of domperidone with pergolide allows quick titration of pergolide dose in the treatment of Parkinson's disease
    Subutay, NO
    Oztekin, MF
    [J]. MOVEMENT DISORDERS, 2004, 19 : S280 - S280
  • [29] Pergolide and cardiac valvulopathy in Parkinson disease
    Jaruchawalit, N.
    Boonkongchuen, P.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S292 - S292
  • [30] Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
    Van Camp, G
    Flamez, A
    Cosyns, B
    Weytjens, C
    Muyldermans, L
    Van Zandijcke, M
    De Sutter, J
    Santens, P
    Decoodt, P
    Moerman, C
    Schoors, D
    [J]. LANCET, 2004, 363 (9416): : 1179 - 1183